The problem is usually not one of legality but of optimization, so it's hard to "fix" without using a heavy hand. You can't force companies to invest in cures r

The problem is usually not one of legality but of optimization, so it's hard to "fix" without using a heavy hand. You can't force companies to invest in cures rather than treatment, especially at the cost of profit. And many individual parties will reach the same conclusion independently, with no need for collusion [0]. In this case it's not hard to arrive at the conclusion that: > While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow. > the success of [the cure] has gradually exhausted the available pool of treatable patients [0] https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patie...